Barclays’s OptimizeRx OPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $93.4K | Sell |
11,186
-3,799
| -25% | -$27.4K | ﹤0.01% | 4332 |
|
|
2026
Q2 | $85.7K | Buy |
14,985
+10,395
| +226% | +$59.8K | ﹤0.01% | 4110 |
|
|
2026
Q1 | $28.8K | Sell |
4,590
-22,851
| -83% | -$212K | ﹤0.01% | 4492 |
|
|
2025
Q4 | $336K | Buy |
27,441
+4,317
| +19% | +$70.5K | ﹤0.01% | 4075 |
|
|
2025
Q3 | $474K | Sell |
23,124
-7,493
| -24% | -$119K | ﹤0.01% | 3847 |
|
|
2025
Q2 | $413K | Buy |
30,617
+8,528
| +39% | +$93.3K | ﹤0.01% | 3867 |
|
|
2025
Q1 | $191K | Sell |
22,089
-8,485
| -28% | -$51.9K | ﹤0.01% | 4067 |
|
|
2024
Q4 | $149K | Buy |
30,574
+3,640
| +14% | +$20.3K | ﹤0.01% | 4435 |
|
|
2024
Q3 | $208K | Buy |
26,934
+21,060
| +359% | +$187K | ﹤0.01% | 4256 |
|
|
2024
Q2 | $58.7K | Sell |
5,874
-5,222
| -47% | -$57.4K | ﹤0.01% | 4138 |
|
|
2024
Q1 | $135K | Sell |
11,096
-11,074
| -50% | -$161K | ﹤0.01% | 4317 |
|
|
2023
Q4 | $317K | Buy |
22,170
+19,357
| +688% | +$186K | ﹤0.01% | 4170 |
|
|
2023
Q3 | $21.9K | Sell |
2,813
-492
| -15% | -$5.35K | ﹤0.01% | 4159 |
|
|
2023
Q2 | $47.2K | Sell |
3,305
-5,137
| -61% | -$73.2K | ﹤0.01% | 3861 |
|
|
2023
Q1 | $124K | Buy |
8,442
+265
| +3% | +$4.43K | ﹤0.01% | 4068 |
|
|
2022
Q4 | $137K | Buy |
8,177
+3,229
| +65% | +$55.8K | ﹤0.01% | 4049 |
|
|
2022
Q3 | $73K | Sell |
4,948
-680
| -12% | -$13.4K | ﹤0.01% | 3654 |
|
|
2022
Q2 | $154K | Sell |
5,628
-9,040
| -62% | -$268K | ﹤0.01% | 3573 |
|
|
2022
Q1 | $553K | Sell |
14,668
-7,814
| -35% | -$346K | ﹤0.01% | 2839 |
|
|
2021
Q4 | $1.4M | Sell |
22,482
-6,407
| -22% | -$486K | ﹤0.01% | 2604 |
|
|
2021
Q3 | $2.47M | Buy |
28,889
+25,845
| +849% | +$1.62M | ﹤0.01% | 2164 |
|
|
2021
Q2 | $188K | Sell |
3,044
-10,599
| -78% | -$539K | ﹤0.01% | 3582 |
|
|
2021
Q1 | $665K | Buy |
13,643
+8,848
| +185% | +$427K | ﹤0.01% | 3017 |
|
|
2020
Q4 | $149K | Sell |
4,795
-1,868
| -28% | -$45.8K | ﹤0.01% | 3938 |
|
|
2020
Q3 | $139K | Sell |
6,663
-1,298
| -16% | -$22.3K | ﹤0.01% | 4062 |
|
|
2020
Q2 | $103K | Buy |
7,961
+3,360
| +73% | +$36.5K | ﹤0.01% | 4495 |
|
|
2020
Q1 | $42K | Sell |
4,601
-12,693
| -73% | -$120K | ﹤0.01% | 5330 |
|
|
2019
Q4 | $178K | Buy |
17,294
+6,891
| +66% | +$78.1K | ﹤0.01% | 5121 |
|
|
2019
Q3 | $151K | Buy |
10,403
+2,678
| +35% | +$41.4K | ﹤0.01% | 5164 |
|
|
2019
Q2 | $125K | Sell |
7,725
-9,013
| -54% | -$122K | ﹤0.01% | 5512 |
|
|
2019
Q1 | $213K | Buy |
+16,738
| New | +$218K | ﹤0.01% | 4773 |
|
Other funds holding OPRX
MBAM
Barclays's OPRX Position: Q3 2026 in Review
Barclays reduced its OptimizeRx (OPRX) stake by 25% in Q3 2026, selling an estimated $27.4K and leaving 11,186 shares worth $93.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4332.
Barclays first reported a position in OPRX in Q1 2019 and has held it in 31 quarters since. The position peaked at $2.47M in Q3 2021. 101 funds tracked by Wall St. Rank hold OPRX as of Q3 2026.
- Barclays held 11,186 shares of OptimizeRx worth $93.4K as of Q3 2026.
- Barclays sold 3,799 OptimizeRx shares in Q3 2026, an estimated $27.4K.
- OptimizeRx made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4332 holding.
- Barclays first reported a position in OptimizeRx in Q1 2019 and has held it in 31 quarters since.
- Barclays's OptimizeRx position peaked at $2.47M in Q3 2021.
- 101 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.